Protein biomarker analysis of primary peyronie's disease cells

Journal of Sexual Medicine

Volumn 7, Issue 1 PART 1, 2010, Pages 99-106

  De Young, Ling X ^a   Bella, Anthony J ^b   O'Gorman, David B ^c   Gan, Bing S ^d   Lim, Kok B ^e   Brock, Gerald B ^f  

^a LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Peyronie's disease cell culture models; Protein expression; Tunica albuginea; Wound healing; catenin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; BIOLOGICAL MARKER; FIBRONECTIN; HEAT SHOCK PROTEIN 47; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FIBROBLAST CULTURE; FIBROSIS; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; PATHOGENESIS; PEYRONIE DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TUNICA ALBUGINEA; UPREGULATION; WESTERN BLOTTING; WOUND HEALING;

EID: 74049126484     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01556.x     Document Type: Article

References (37)

1. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004, 171:2350-3.
2. Weidner W, Schroeder-Printzen I, Weiske WH, Vosshenrich R. Sexual dysfunction in Peyronie's disease: An analysis of 222 patients without previous local plaque therapy. J Urol 1997, 157:325-8.
3. Devine CJ, Somers KD, Jordan SG, Schlossberg SM. Proposal: Trauma as the cause of the Peyronie's lesion. J Urol 1997, 157:285-90.
4. Jarow JP, Lowe FC. Penile trauma: An etiologic factor in Peyronie's disease and erectile dysfunction. J Urol 1997, 158:1388-90.
5. Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol 1997, 157:311-5.
6. el Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997, 158:1391-4.
7. el Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997, 158:2284-90.
8. Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: Phenotypic, genotypic and functional analyses. Int J Impot Res 2002, 14:397-405.
9. Nachtsheim DA, Rearden A. Peyronie's disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology. J Urol 1996, 156:1330-4.
10. Schiavino D, Sasso F, Nucera E, Alcini E, Gulino G, Milani A, Patriarca G. Immunologic findings in Peyronie's disease: A controlled study. Urology 1997, 50:764-8.
11. Cantini LP, Ferrini MG, Vernet D, Magee TR, Qian A, Gelfand RA, Rajfer J, Gonzalez-Cadavid NF. Profibrotic role of myostatin in Peyronie's disease. J Sex Med 2008, 5:1607-22.
12. Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts. J Urol 2008, 179:2447-55.
13. Ryu JK, Piao S, Shin HY, Choi MJ, Zhang LW, Jin HR, Kim WJ, Han JY, Hong SS, Park SH, Lee SJ, Kim IH, Lee CR, Kim DK, Mamura M, Kim SJ, Suh JK. IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease. J Sex Med 2009, 6:1284-96.
14. Anderson MS, Shankey TV, Lubrano T, Mulhall JP. Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents. Int J Impot Res 2000, 12(3):S25-31. suppl
15. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Jannini EA, Vespasiani G. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004, 171:1605-8.
16. Muller A, Mulhall JP. Peyronie's disease intervention trials: Methodological challenges and issues. J Sex Med 2009, 6:848-61.
17. Gonzalez-Cadavid NF, Rajfer J. Experimental models of Peyronie's disease. Implications for new therapies. J Sex Med 2009, 6:303-13.
18. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990, 144:1376-9.
19. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie's disease. J Urol 2002, 168:1075-9.
20. Grasso M, Lania C, Blanco S, Limonta G. The natural history of Peyronie's disease. Arch Esp Urol 2007, 60:326-31.
21. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 5:4589-96.
22. Li J, Zhao J, Yu X, Lange J, Kuerer H, Krishnamurthy S, Schilling E, Khan SA, Sukumar S, Chan DW. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res 2005, 11:8312-20.
23. Melle C, Ernst G, Schimmel B, Bleul A, Kaufmann R, Hommann M, Richter KK, Daffner W, Settmacher U, Claussen U, von Eggeling F. Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. J Proteome Res 2005, 4:1799-804.
24. Somers KD, Dawson DM, Wright GL, Leffell MS, Rowe MJ, Bluemink GG, Vande Berg JS, Gleischman SH, Devine CJ, Horton CE. Cell culture of Peyronie's disease plaque and normal penile tissue. J Urol 1982, 127:585-8.
25. Lin CS, Lin G, Wang Z, Maddah SA, Lue TF. Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie's disease. Biochem Biophys Res Commun 2002, 295:1014-9.
26. Ralph DJ, Mirakian R, Pryor JP, Bottazzo GF. The immunological features of Peyronie's disease. J Urol 1996, 155:159-62.
27. Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J, Gonzalez-Cadavid NF. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 2002, 7:262-76.
28. Vernet D, Nolazco G, Cantini L, Magee TR, Qian A, Rajfer J, Gonzalez-Cadavid NF. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: Implications for Peyronie's disease. Biol Reprod 2005, 73:1199-210.
29. Badid C, Mounier N, Costa AM, Desmouliere A. Role of myofibroblasts during normal tissue repair and excessive scarring: Interest of their assessment in nephropathies. Histol Histopathol 2000, 15:269-80.
30. Howard JC, Varallo VM, Ross DC, Roth JH, Faber KJ, Alman B, Gan BS. Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren's disease cells are regulated by tension in vitro. BMC Musculoskelet Disord 2003, 4:16.
31. Varallo VM, Gan BS, Seney S, Ross DC, Roth JH, Richards RS, McFarlane RM, Alman B, Howard JC. Beta-catenin expression in Dupuytren's disease: Potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene 2003, 22:3680-4.
32. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003, 162:1495-502.
33. Masszi A, Fan L, Rosivall L, McCulloch CA, Rotstein OD, Mucsi I, Kapus A. Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-to-myofibroblast transition: Role for beta-catenin. Am J Pathol 2004, 165:1955-67.
34. Howard JC, Varallo VM, Ross DC, Faber KJ, Roth JH, Seney S, Gan BS. Wound healing-associated proteins Hsp47 and fibronectin are elevated in Dupuytren's contracture. J Surg Res 2004, 117:232-8.
35. Iwashita T, Kadota J, Naito S, Kaida H, Ishimatsu Y, Miyazaki M, Ozono Y, Kohno S. Involvement of collagen-binding heat shock protein 47 and procollagen type I synthesis in idiopathic pulmonary fibrosis: Contribution of type II pneumocytes to fibrosis. Hum Pathol 2000, 31:1498-505.
36. Yokota S, Kubota H, Matsuoka Y, Naitoh M, Hirata D, Minota S, Takahashi H, Fujii N, Nagata K. Prevalence of HSP47 antigen and autoantibodies to HSP47 in the sera of patients with mixed connective tissue disease. Biochem Biophys Res Commun 2003, 303:413-8.
37. Domes T, De Young L, Brock G. Developing a prognostic tool for Peyronie's disease: Validation of a percutaneous aspiration technique. Can Urol Assoc J 2007, 1:310.